The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2022 | An insight into the heterogeneity of SMM and how genetic subtypes impact risk of disease progression
Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, shares some insights into the heterogeneity of smoldering multiple myeloma (SMM) and challenges in diagnosing patients. Dr Ghobrial also explains how genomic and epigenetic information can help clinicians better understand a patient’s risk of progression to multiple myeloma. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
